{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:25:55Z","timestamp":1773116755846,"version":"3.50.1"},"reference-count":43,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172654"],"award-info":[{"award-number":["82172654"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570537"],"award-info":[{"award-number":["81570537"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974074"],"award-info":[{"award-number":["81974074"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2020JJ5949"],"award-info":[{"award-number":["2020JJ5949"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["82172654"],"award-info":[{"award-number":["82172654"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["81570537"],"award-info":[{"award-number":["81570537"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["81974074"],"award-info":[{"award-number":["81974074"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2020JJ5949"],"award-info":[{"award-number":["2020JJ5949"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Dipeptidase 2 (DPEP2) is a dipeptidyl peptidase that plays an important role in the hydrolysis of leukotriene D4 (LTD4) to leukotriene E4 (LTE4). Previous studies have suggested that LTD4 promotes tumor progression and survival in non-small cell lung cancer (NSCLC). Therefore, we hypothesized that DPEP2 may play a pivotal role in this tumor. Given that lung adenocarcinoma (LUAD) is the most common subtype of NSCLC, our study aimed to examine the expression and function of DPEP2 in LUAD. Based on bioinformatics and the analysis of clinical samples, our findings revealed that DPEP2 is highly expressed in normal lung tissues, but downregulated in LUAD tissues, and its expression levels were significantly associated with clinical indicators of tumor grade and prognosis. Pathway enrichment analysis showed that DPEP2 is involved in biological processes such as chemokine signaling pathways, leukocyte trans-endothelial migration, and humoral immune responses in LUAD. In addition, DPEP2 expression was significantly associated with various immune cells, especially monocytes\u2013macrophages. Single-cell transcriptome data further confirmed the expression of DPEP2 dominantly in macrophages from normal lung tissues. Analysis of the TCIA database revealed that high DPEP2 expression is associated with a stronger response to immune checkpoint inhibitors such as CTLA4 and PD1, and determines sensitivity to LUAD therapeutic agents. Furthermore, we found that DPEP2 inhibits the migration and invasion of LUAD cells. Therefore, DPEP2 may serve as a potential immune biomarker and therapeutic target for LUAD, providing novel therapeutic approaches for this disease.<\/jats:p>","DOI":"10.3390\/ph16060871","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T02:56:34Z","timestamp":1686624994000},"page":"871","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Integrated Single-Cell and Transcriptome Sequencing Analyses Identify Dipeptidase 2 as an Immune-Associated Prognostic Biomarker for Lung Adenocarcinoma"],"prefix":"10.3390","volume":"16","author":[{"given":"Xiangqian","family":"Zhang","sequence":"first","affiliation":[{"name":"NHC Key Laboratory of Cancer Proteomics & State Local Joint Engineering Laboratory for Anticancer Drugs, Department of Oncology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfan","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Life Sciences, Hunan Normal University, Changsha 410008, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Zhang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Cancer Proteomics & State Local Joint Engineering Laboratory for Anticancer Drugs, Department of Oncology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8139-6892","authenticated-orcid":false,"given":"Yongheng","family":"Chen","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Cancer Proteomics & State Local Joint Engineering Laboratory for Anticancer Drugs, Department of Oncology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11739-021-02833-6","article-title":"Lung cancer interstitial lung diseases: The lack of prognostic impact of lung cancer in, I.P.F","volume":"17","author":"Carobene","year":"2022","journal-title":"Intern. Emerg. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: Current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"105.e11","DOI":"10.1016\/j.urolonc.2021.11.001","article-title":"Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prospective, blinded clinical trial","volume":"40","author":"CCochetti","year":"2022","journal-title":"Urol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0163-7258(90)90035-Z","article-title":"Leukotrienes and inflammation","volume":"46","author":"Brain","year":"1990","journal-title":"Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2022087118","DOI":"10.1073\/pnas.2022087118","article-title":"The CysLT(2)R receptor mediates leukotriene C(4)-driven acute and chronic itch","volume":"118","author":"Voisin","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3748\/wjg.v20.i4.968","article-title":"Cysteinyl leukotrienes and their receptors: Bridging inflammation and colorectal cancer","volume":"20","author":"Savari","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1464-410X.2004.04847.x","article-title":"Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: Chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine","volume":"93","author":"Oomen","year":"2004","journal-title":"BJU Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2018.11.033","article-title":"Exosomes and cells from lung cancer pleural exudates transform LTC4 to LTD4, promoting cell migration and survival via CysLT1","volume":"444","author":"Lukic","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ejca.2009.12.022","article-title":"Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer","volume":"46","author":"Magnusson","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1096\/fj.02-0899fje","article-title":"Identification of two additional members of the membrane-bound dipeptidase family","volume":"17","author":"Habib","year":"2003","journal-title":"FASEB J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fcimb.2019.00057","article-title":"Dpep2 Emerging as a Modulator of Macrophage Inflammation Confers Protection Against CVB3-Induced Viral Myocarditis","volume":"9","author":"Yang","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e21000162022","DOI":"10.1002\/prca.202100016","article-title":"Integrating SWATH-MS proteomics and transcriptome analysis to preliminarily identify three DEGs as biomarkers for proliferative diabetic retinopathy","volume":"16","author":"Wu","year":"2022","journal-title":"Proteom. Clin. Appl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/all.13726","article-title":"Dysregulated fatty acid metabolism in nasal polyp-derived eosinophils from patients with chronic rhinosinusitis","volume":"74","author":"Miyata","year":"2019","journal-title":"Allergy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1084\/jem.191.3.515","article-title":"Negative regulation of phagocytosis in murine macrophages by the Src kinase family member, Fgr","volume":"191","author":"Gresham","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12935-022-02517-x","article-title":"AMICA1 is a diagnostic and prognostic biomarker and induces immune cells infiltration by activating cGAS-STING signaling in lung adenocarcinoma","volume":"22","author":"Feng","year":"2022","journal-title":"Cancer Cell. Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","article-title":"Macrophages at the interface of the co-evolving cancer ecosystem","volume":"186","author":"Kloosterman","year":"2023","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9332","DOI":"10.7150\/thno.47137","article-title":"USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer","volume":"10","author":"Dai","year":"2020","journal-title":"Theranostics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","article-title":"Targeting macrophages in cancer immunotherapy","volume":"6","author":"Duan","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: From CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","article-title":"Macrophage-Based Approaches for Cancer Immunotherapy","volume":"81","author":"Anderson","year":"2021","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12016-019-08753-w","article-title":"Role of Mast Cells in Shaping the Tumor Microenvironment","volume":"58","author":"Komi","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e20020542020","DOI":"10.1002\/adma.202002054","article-title":"Engineering Macrophages for Cancer Immunotherapy and Drug Delivery","volume":"32","author":"Xia","year":"2020","journal-title":"Adv. Mater."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41575-021-00471-z","article-title":"Single-cell RNA sequencing in pancreatic cancer","volume":"18","author":"Han","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s41467-018-03900-x","article-title":"Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy","volume":"9","author":"Anker","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: Mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: Updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","article-title":"ROS1-dependent cancers\u2014Biology, diagnostics and therapeutics","volume":"18","author":"Drilon","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-21-2138","article-title":"Molecular Pathways and Mechanisms of BRAF in Cancer Therapy","volume":"28","author":"Poulikakos","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jtho.2022.10.015","article-title":"MET alterations in NSCLC-Current Perspectives and Future Challenges","volume":"18","author":"Remon","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: Update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"30S","DOI":"10.1378\/chest.103.1_Supplement.30S","article-title":"Postoperative chemotherapy for non-small-cell lung cancer","volume":"103","author":"Holmes","year":"1993","journal-title":"Chest"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1080\/14737140.2021.1991316","article-title":"Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy","volume":"21","author":"Sohail","year":"2021","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1097\/JTO.0b013e318174e9be","article-title":"The current status and evolving role of sunitinib in non-small cell lung cancer","volume":"3","author":"Socinski","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1200\/JCO.2010.30.5474","article-title":"Phase II study of dasatinib in patients with advanced non-small-cell lung cancer","volume":"28","author":"Johnson","year":"2010","journal-title":"J. Clin. Oncol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/6\/871\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:53:24Z","timestamp":1760126004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/6\/871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ph16060871"],"URL":"https:\/\/doi.org\/10.3390\/ph16060871","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]}}}